Navigation Links
Archemix Announces Completion of Phase 1 Trial of ARC1779

rial blockage."

"We are developing a pipeline of aptamer therapeutics with a proprietary focus in acute cardiovascular and hematological diseases," commented Errol De Souza, Ph.D., President and Chief Executive Officer, Archemix. "The advancement of ARC1779 into Phase 2 will be a key milestone in the development of our broad product portfolio."

About Aptamers

Aptamers are single-stranded nucleic acids that form well-defined three dimensional shapes, allowing them to bind target molecules in a manner that is conceptually similar to antibodies. Aptamers combine the optimal characteristics of small molecules and antibodies, including high specificity and affinity, chemical stability, low immunogenicity and the ability to target protein-protein interactions. In contrast to monoclonal antibodies, aptamers are chemically synthesized rather than biologically expressed.

About Archemix

Archemix Corp. is a privately-held biopharmaceutical company developing aptamers as a class of directed therapeutics for the prevention and treatment of human disease. The company is leveraging its proprietary drug discovery technology to fuel the growth of its development portfolio, which is primarily focused on acute cardiovascular and hematology diseases and cancer. Archemix's broad product pipeline, being developed both by the company as well as its licensees, includes multiple investigational compounds at various stages of development, several of which are moving into Phase 2 clinical trials. Archemix's lead proprietary product, ARC1779, a selective platelet inhibitor, is anticipated to start a Phase 2a and Phase 1b clinical trial before the end of 2007. Archemix' leadership position in intellectual property, technology and expertise relating to aptamers has enabled it to form numerous collaborations with biotechnology and pharmaceutical collaborators, including Merck Serono, Pfizer Inc., Elan Pharma, Nuvelo, Inc., Antisoma plc., and Regado Biosciences.
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Archemix Announces Completion Phase Trial ARC1779
(Date:10/1/2014)... Switzerland , October 1, 2014 /PRNewswire/ ... Clinical Genomics and Next Generation Sequencing (NGS) data analysis, ... to run full cystic fibrosis analysis in a single ... and characterisation of all types of variants in a ... Until now, it has not been possible to ...
(Date:9/30/2014)... Sept. 30, 2014 This report analyzes the worldwide ... following Product Categories: Enteral Feeding Pumps, Nasogastric Tubes, and Others. ... US Canada, Japan , Europe ... America , and Rest of World. Annual estimates and ... a six-year historic analysis is provided for these markets. ...
(Date:9/30/2014)... -- Hologic, Inc. (NASDAQ: HOLX ), today announced ... Executive Officer, will preside over the NASDAQ Stock Market ... of Breast Cancer Awareness Month. In his remarks, Mr. ... important benefits of Hologic,s 3D Mammography technology, the only ... to traditional mammography. This is the ninth ...
Breaking Medicine Technology:Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3
... N.J. , April 26 Watson Pharmaceuticals, ... the U.S. Court of Appeals for the Federal Circuit ... District Court decision that the asserted claims of ALZA,s ... invalid.  The original suit by ALZA Corporation and McNeil-PPC, ...
... April 26 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced ... calls focused on the drugs in Isis, development pipeline.  The second call of ... Wednesday, April 28, 2010 at 12:00 p.m. ET .  This ... , , ...
Cached Medicine Technology:Watson Says Appeals Court Affirms Concerta(R) Patent Invalid 2Watson Says Appeals Court Affirms Concerta(R) Patent Invalid 3Isis Pharmaceuticals to Discuss Its Metabolic Franchise in a Conference Call on Wednesday, April 28 2Isis Pharmaceuticals to Discuss Its Metabolic Franchise in a Conference Call on Wednesday, April 28 3
(Date:10/1/2014)... October 01, 2014 Insuranceragents.info has ... a good life insurance plan for vulnerable family members. ... vulnerable family members. Providers in the family should always ... cause financial hardships for the rest of the family. ... policies. Families can benefit more from temporary coverage or ...
(Date:10/1/2014)... October 01, 2014 Phoseon Technology, the ... continues to expand the business worldwide. This rapid growth ... additional capacity for manufacturing efforts. The company has experienced ... five years and expects this growth to continue in ... technology gains worldwide adoption. , “We are very ...
(Date:10/1/2014)... A new genetic finding from Duke Medicine suggests that ... depression might also be hard-wired to gain weight when ... disease. , An estimated 13 percent of people, all ... and knowing this could help them reduce heart disease ... and stress management. , "Genetic susceptibility, psychosocial stress and ...
(Date:10/1/2014)... Jersey City, NJ (PRWEB) October 01, 2014 ... sticking with their intentions to lose weight and their dieting ... in unhealthy, fatty foods. Including hormone diet treatments ... not only allows patients to see fast and effective weight ... diet and begin forming healthy habits to maintain their weight ...
(Date:10/1/2014)... 2014 On Sept. 9, Chapín Coffee ... the Martha Stewart American Made Awards (MSAMAs), an annual ... country in the fields of crafts, design, food and ... a finalist in the MSAMAs, which celebrates entrepreneurs and ... improving local communities and changing the way we shop, ...
Breaking Medicine News(10 mins):Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2
... the form of percutaneous coronary intervention (PCI) is now ... infarction. New European guidelines issued in November 2008 emphasised ... to restore blood flow to the heart and improve ... in patients with stable coronary artery disease; PCI has ...
... Construction Company, the nation,s leading builder of healthcare facilities, ... proceed with the $42 million Phase Two expansion to ... start in March 2009 with completion scheduled for March ... plant, emergency rooms, ICU, CCU, three operating rooms and ...
... PARK, Ill., Feb. 6 Abbott ( NYSE: ABT ... Antitrust,Improvements Act of 1976 (HSR) applicable to Abbott,s cash ... common stock of Advanced Medical,Optics (AMO) expired last night ... The expiration of the HSR waiting period satisfies ...
... of 7 HIV+ Patients Receiving Dapsone Therapy at Significant ... IRVINE, Calif., Feb. 6 Masimo (Nasdaq: ... Motion and Low-Perfusion pulse oximetry, today announced that a ... Medicine 38th Critical Care Congress suggests providers should consider ...
... revenues increase by 35% over same period in ... are in Canadian dollars unless otherwise noted),BELLEVILLE, ON, ... (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, ... of its 2009 fiscal year, ending December 31, ...
... a new study shows that losing weight is perhaps the ... disorders, according to a new study in the American ... the American Thoracic Society,s three peer-reviewed journals. , Weight ... fancy high-tech treatment, but it is an exciting therapy for ...
Cached Medicine News:Health News:Efficacy of stents is improved when their placement is determined by arterial blood flow measurement 2Health News:Turner to Manage Construction of $42 Million Expansion of Northern Inyo Hospital in Bishop, Calif. 2Health News:Abbott Acquisition of Advanced Medical Optics Clears U.S. Antitrust Review 2Health News:Abbott Acquisition of Advanced Medical Optics Clears U.S. Antitrust Review 3Health News:New Clinical Study Presented at the Society for Critical Care Medicine Shows Value of Pulse CO-Oximetry(TM) to Identify Acquired Methemoglobinemia 2Health News:New Clinical Study Presented at the Society for Critical Care Medicine Shows Value of Pulse CO-Oximetry(TM) to Identify Acquired Methemoglobinemia 3Health News:New Clinical Study Presented at the Society for Critical Care Medicine Shows Value of Pulse CO-Oximetry(TM) to Identify Acquired Methemoglobinemia 4Health News:Bioniche Reports Fiscal 2009 Second Quarter 2Health News:Bioniche Reports Fiscal 2009 Second Quarter 3Health News:Bioniche Reports Fiscal 2009 Second Quarter 4Health News:Bioniche Reports Fiscal 2009 Second Quarter 5Health News:Bioniche Reports Fiscal 2009 Second Quarter 6Health News:Bioniche Reports Fiscal 2009 Second Quarter 7Health News:Bioniche Reports Fiscal 2009 Second Quarter 8Health News:Bioniche Reports Fiscal 2009 Second Quarter 9Health News:Losing weight can cure obstructive sleep apnea in overweight patients 2
... sensitivity (threshold) testing provides clinically beneficial ... ophthalmic conditions. Dark adaptometry is useful ... retinal degenerations, senile miosis, high myopia, ... conditions, while whole-field scotopic sensitivity has ...
... The MFERG is available in conjunction with ... UTAS-E3000mf or EPIC-4000 or as a stand-alone ... visual electrodiagnostic test uses a software controlled ... to stimulate many areas of the retina ...
... Amplifier (UBA-4204) from LKC Technologies, ... amplification and complete electrical isolation ... problems of DC drifting, 50/60Hz ... make the amplifier ideal for ...
... to facilitate an arthrodesis, either by an ... cages allowing radicular compression by restoring the ... of the foramina, which in turn enhances ... major lumbar instabilities.,CC cages are made of ...
Medicine Products: